Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kari M Morrissey

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Annual Review of Pharmacology and Toxicology|November 13, 2012
Renal transporters in drug developmentKari M Morrissey, Sophie L Stocker, Matthias B Wittwer, et al.
Clinical Pharmacokinetics|October 29, 2015
The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy VolunteersKari M Morrissey, Sophie L Stocker, Eugene C Chen, et al.
Traffic (Copenhagen, Denmark)|April 29, 2006
Expanding the role of the dynein regulatory complex to non-axonemal functions: association of GAS11 with the Golgi apparatusJessica R Colantonio, Janine M Bekker, Sarah J Kim, et al.
Clinical Pharmacology and Therapeutics|November 22, 2019
The Patient-Centered Future of Clinical PharmacologyMohamed H Shahin, Susan Abdel-Rahman, Dan Hartman, et al.
Bioinformatics (Oxford, England)|July 10, 2018
Computational analysis of kinase inhibitor selectivity using structural knowledgeYu-Chen Lo, Tianyun Liu, Kari M Morrissey, et al.
Journal of Medicinal Chemistry|December 18, 2012
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modelingMatthias B Wittwer, Arik A Zur, Natalia Khuri, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 28, 2017
Combining "Bottom-up" and "Top-down" Approaches to Assess the Impact of Food and Gastric pH on Pictilisib (GDC-0941) PharmacokineticsTong Lu, Grazyna Fraczkiewicz, Laurent Salphati, et al.
Cancer Chemotherapy and Pharmacology|September 23, 2019
Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing settingKari M Morrissey, Mathilde Marchand, Hina Patel, et al.
Breast Cancer Research : BCR|September 7, 2018
A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancerPatrick Schöffski, Sara Cresta, Ingrid A Mayer, et al.
British Journal of Clinical Pharmacology|April 12, 2019
Investigation of the absolute bioavailability and human mass balance of navoximod, a novel IDO1 inhibitorShuguang Ma, Julia Suchomel, Evelyn Yanez, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Annual Review of Pharmacology and Toxicology|November 13, 2012
Renal transporters in drug developmentKari M Morrissey, Sophie L Stocker, Matthias B Wittwer, et al.
Clinical Pharmacokinetics|October 29, 2015
The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy VolunteersKari M Morrissey, Sophie L Stocker, Eugene C Chen, et al.
Traffic (Copenhagen, Denmark)|April 29, 2006
Expanding the role of the dynein regulatory complex to non-axonemal functions: association of GAS11 with the Golgi apparatusJessica R Colantonio, Janine M Bekker, Sarah J Kim, et al.
Clinical Pharmacology and Therapeutics|November 22, 2019
The Patient-Centered Future of Clinical PharmacologyMohamed H Shahin, Susan Abdel-Rahman, Dan Hartman, et al.
Bioinformatics (Oxford, England)|July 10, 2018
Computational analysis of kinase inhibitor selectivity using structural knowledgeYu-Chen Lo, Tianyun Liu, Kari M Morrissey, et al.
Journal of Medicinal Chemistry|December 18, 2012
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modelingMatthias B Wittwer, Arik A Zur, Natalia Khuri, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 28, 2017
Combining "Bottom-up" and "Top-down" Approaches to Assess the Impact of Food and Gastric pH on Pictilisib (GDC-0941) PharmacokineticsTong Lu, Grazyna Fraczkiewicz, Laurent Salphati, et al.
Cancer Chemotherapy and Pharmacology|September 23, 2019
Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing settingKari M Morrissey, Mathilde Marchand, Hina Patel, et al.
Breast Cancer Research : BCR|September 7, 2018
A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancerPatrick Schöffski, Sara Cresta, Ingrid A Mayer, et al.
British Journal of Clinical Pharmacology|April 12, 2019
Investigation of the absolute bioavailability and human mass balance of navoximod, a novel IDO1 inhibitorShuguang Ma, Julia Suchomel, Evelyn Yanez, et al.
Pageof 2